Akebia Therapeutics’ (AKBA) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of Akebia Therapeutics (NASDAQ:AKBAFree Report) in a research report released on Wednesday,Weiss Ratings reports.

A number of other research firms have also weighed in on AKBA. Zacks Research lowered shares of Akebia Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Wall Street Zen lowered shares of Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 13th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.75.

Read Our Latest Stock Report on AKBA

Akebia Therapeutics Trading Down 4.8%

AKBA stock opened at $2.75 on Wednesday. The company has a current ratio of 1.98, a quick ratio of 1.84 and a debt-to-equity ratio of 1.61. Akebia Therapeutics has a 12-month low of $1.27 and a 12-month high of $4.08. The stock has a market cap of $729.14 million, a price-to-earnings ratio of -16.18 and a beta of 0.68. The business’s 50-day moving average is $3.04 and its 200 day moving average is $2.98.

Institutional Trading of Akebia Therapeutics

Institutional investors have recently made changes to their positions in the company. Unified Investment Management raised its position in shares of Akebia Therapeutics by 47.8% during the 1st quarter. Unified Investment Management now owns 17,000 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 5,500 shares during the period. E Fund Management Co. Ltd. raised its position in shares of Akebia Therapeutics by 51.9% during the 1st quarter. E Fund Management Co. Ltd. now owns 19,311 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 6,595 shares during the period. Abel Hall LLC purchased a new stake in shares of Akebia Therapeutics during the 2nd quarter valued at approximately $39,000. Baird Financial Group Inc. raised its position in shares of Akebia Therapeutics by 23.0% during the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 4,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Akebia Therapeutics during the 2nd quarter valued at approximately $59,000. Hedge funds and other institutional investors own 33.92% of the company’s stock.

About Akebia Therapeutics

(Get Free Report)

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.

Read More

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.